lansoprazole and transforming growth factor beta

lansoprazole has been researched along with transforming growth factor beta in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	2 (66.67)	24.3611
2020's	1 (33.33)	2.80

Authors

Authors	Studies
Ichinose, M; Iguchi, M; Ito, T; Kitano, M; Nishi, T; Tamai, H; Tsuruo, Y; Ueyama, T; Yamagishi, N; Yamamoto, Y	1
Feldon, SE; Hammond, CL; Phipps, RP; Roztocil, E; Woeller, CF	1
Alhassanin, SA; El-Berri, EI; El-Haggar, SM; Hegazy, SK	1

Trials

1 trial(s) available for lansoprazole and transforming growth factor beta

Article	Year
Comparative randomized trial evaluating the effect of proton pump inhibitor versus histamine 2 receptor antagonist as an adjuvant therapy in diffuse large B-cell lymphoma. Medical oncology (Northwood, London, England), 2021, 01-04, Volume: 38, Issue:1 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Caspase 3; Cyclophosphamide; Doxorubicin; Famotidine; Female; Histamine H2 Antagonists; Humans; Lansoprazole; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Prednisone; Proton Pump Inhibitors; Rituximab; Transforming Growth Factor beta; Treatment Outcome; Vincristine	2021

Article

Year

Comparative randomized trial evaluating the effect of proton pump inhibitor versus histamine 2 receptor antagonist as an adjuvant therapy in diffuse large B-cell lymphoma.

Medical oncology (Northwood, London, England), 2021, 01-04, Volume: 38, Issue:1

Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Caspase 3; Cyclophosphamide; Doxorubicin; Famotidine; Female; Histamine H2 Antagonists; Humans; Lansoprazole; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Prednisone; Proton Pump Inhibitors; Rituximab; Transforming Growth Factor beta; Treatment Outcome; Vincristine

2021

Other Studies

2 other study(ies) available for lansoprazole and transforming growth factor beta

Article	Year
Lansoprazole prevents the progression of liver fibrosis in non-alcoholic steatohepatitis model rats. The Journal of pharmacy and pharmacology, 2018, Volume: 70, Issue:3 Topics: Animals; Aspartate Aminotransferases; Diet; Disease Models, Animal; Disease Progression; Heme Oxygenase (Decyclizing); Interleukin-6; Lansoprazole; Liver Cirrhosis; Male; NF-E2-Related Factor 2; Non-alcoholic Fatty Liver Disease; Rats; Transforming Growth Factor beta	2018
Proton pump inhibitors attenuate myofibroblast formation associated with thyroid eye disease through the aryl hydrocarbon receptor. PloS one, 2019, Volume: 14, Issue:9 Topics: Actins; Calcium-Binding Proteins; Calponins; Cell Differentiation; Cells, Cultured; Cicatrix; Collagen; Esomeprazole; Fibroblasts; Graves Ophthalmopathy; HEK293 Cells; Humans; Lansoprazole; Microfilament Proteins; Myofibroblasts; Proton Pump Inhibitors; Receptors, Aryl Hydrocarbon; Transforming Growth Factor beta; Wnt Signaling Pathway	2019

Article

Year

Lansoprazole prevents the progression of liver fibrosis in non-alcoholic steatohepatitis model rats.

The Journal of pharmacy and pharmacology, 2018, Volume: 70, Issue:3

Topics: Animals; Aspartate Aminotransferases; Diet; Disease Models, Animal; Disease Progression; Heme Oxygenase (Decyclizing); Interleukin-6; Lansoprazole; Liver Cirrhosis; Male; NF-E2-Related Factor 2; Non-alcoholic Fatty Liver Disease; Rats; Transforming Growth Factor beta

2018

Proton pump inhibitors attenuate myofibroblast formation associated with thyroid eye disease through the aryl hydrocarbon receptor.

PloS one, 2019, Volume: 14, Issue:9

Topics: Actins; Calcium-Binding Proteins; Calponins; Cell Differentiation; Cells, Cultured; Cicatrix; Collagen; Esomeprazole; Fibroblasts; Graves Ophthalmopathy; HEK293 Cells; Humans; Lansoprazole; Microfilament Proteins; Myofibroblasts; Proton Pump Inhibitors; Receptors, Aryl Hydrocarbon; Transforming Growth Factor beta; Wnt Signaling Pathway

2019